Passage Bio financials
$4.68−2.60%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$8.3M | -$8.9M | -$13.8M | -$8.7M | -$10.3M | -$16.5M | -$14.3M | -$20.7M | -$17.4M | -$18.1M | -$18.4M | -$28.7M |
| Net income | -$7.8M | -$7.6M | -$13.0M | -$7.7M | -$9.4M | -$15.4M | -$12.7M | -$19.3M | -$16.0M | -$16.7M | -$16.8M | -$27.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-2.44 | $-2.36 | $-4.08 | $-2.44 | $-2.96 | $-4.87 | $-1.42 | $-6.15 | $-5.09 | $-6.00 | $-6.11 | $-9.80 |
| EBITDA | -$10.2M | -$8.8M | -$10.2M | -$8.5M | -$10.2M | -$13.6M | -$14.3M | -$15.1M | -$16.1M | -$17.2M | -$17.6M | -$22.3M |
| Operating cash flow | -$9.2M | -$13.0M | -$6.5M | -$4.9M | -$6.3M | -$13.8M | -$8.4M | -$7.4M | -$13.1M | -$18.9M | -$19.5M | -$19.2M |
| Free cash flow | -$9.2M | -$13.0M | -$6.5M | -$4.9M | -$6.3M | -$13.8M | -$8.5M | -$7.4M | -$13.1M | -$18.9M | -$19.5M | -$19.2M |
| Diluted shares | 3.2M | 3.2M | 3.2M | 3.2M | 3.2M | 3.2M | 9.0M | 3.1M | 3.1M | 2.8M | 2.7M | 2.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $24.2M | $33.3M | $46.3M | $52.8M | $57.6M | $63.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $25.2M | $36.5M | $62.3M | $74.2M | $79.2M | $86.0M |
| Total liabilities | $20.7M | $24.7M | $43.5M | $43.0M | $40.9M | $39.3M |
| Shareholders' equity | $4.5M | $11.8M | $18.8M | $31.1M | $38.3M | $46.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology